Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design.
Joaquim Barreto OliveiraMarilia MartinsMauro PascoaSheila T K MedorimaIsabella BonilhaDaniel Campos JesusCinthia E M CarbonaraKelcia R S QuadrosBarbara AssatoAlessandra M Campos-StafficoGil Guerra JúniorWilson NadruzRodrigo B de OliveiraAndrei C SpositoPublished in: Research square (2023)
The DARE-ESKD-2 trial will provide unprecedented data on the cardiovascular safety and efficacy of SGLT2i in ESKD individuals on dialysis. This study will pave the grounds for improving clinical outcomes of dialysis recipients.